Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication

Background: Elevated triglyceride-rich lipoproteins and reduced high-density lipoproteins (HDL) are associated with the development of intermittent claudication (IC), a life-limiting symptom of peripheral arterial disease. Cilostazol, a potent platelet inhibitor and vasodilator, lowers triglycerides...

Full description

Saved in:
Bibliographic Details
Published in:Atherosclerosis 2003-12, Vol.171 (2), p.337-342
Main Authors: Wang, Tao, Elam, Marshall B., Forbes, William P., Zhong, Jianhua, Nakajima, Katsuyuki
Format: Article
Language:English
Subjects:
Aged
Biological and medical sciences
Cardiovascular pharmacology
Cardiovascular system
Cholesterol - metabolism
Cilostazol
Female
Follow-Up Studies
Humans
Intermittent claudication
Intermittent Claudication - diagnosis
Intermittent Claudication - drug therapy
Lipids
Lipoproteins - drug effects
Lipoproteins - metabolism
Male
Medical sciences
Middle Aged
Pentoxifylline - administration & dosage
Peripheral arterial disease
Peripheral vascular disease
Pharmacology. Drug treatments
Probability
Remnant lipoproteins
Risk Assessment
Severity of Illness Index
Statistics, Nonparametric
Tetrazoles - administration & dosage
Treatment Outcome
Triglycerides
Vasodilator Agents - administration & dosage
Vasodilator agents. Cerebral vasodilators
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Elevated triglyceride-rich lipoproteins and reduced high-density lipoproteins (HDL) are associated with the development of intermittent claudication (IC), a life-limiting symptom of peripheral arterial disease. Cilostazol, a potent platelet inhibitor and vasodilator, lowers triglycerides and increases HDL concentrations in addition to increasing walking distance in patients with intermittent claudication. However, the association of remnant lipoproteins (a more atherogenic subset of triglyceride-rich lipoproteins) and peripheral arterial disease and the effects of cilostazol on remnant lipoproteins have not been studied. Methods and results: We quantified plasma remnant lipoprotein concentrations using the remnant lipoprotein-cholesterol assay (RLP-C). Patients with intermittent claudication ( n=415) had significantly higher remnant lipoprotein concentrations compared to reference subjects ( n=874; 0.31±0.32 versus 0.24±0.17 mmol/l, P
ISSN:0021-9150
1879-1484
DOI:10.1016/j.atherosclerosis.2003.08.017